Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737398 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT01737398 is a Phase 2 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 173 participants.
The verdict
NCT01737398, a Phase 2 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
Interventions
- DRUG Placebo
- DRUG Inotersen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2013-03-15 |
| Est. Completion | 2017-11-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01737398
The ClinicalTrials.gov registry entry for NCT01737398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01737398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01737398 about?
NCT01737398 is a clinical study titled "Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy". The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).
What is the current status of trial NCT01737398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2013-03-15. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT01737398?
The interventions under investigation include: Placebo (DRUG), Inotersen (DRUG).
Who is sponsoring clinical trial NCT01737398?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.